Competition Markets Authority
Phase 2
Administrative timetable
Date of referral: 31 March 2023
Statutory deadline: 5 October 2023
- (17.5.23)
Contact
Issues statement
17 May 2023: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions.
- (17.5.23)
Notice of extension
- (27.4.23)
Inquiry group appointed
31 March 2021: The CMA has appointed the inquiry group.Kirstin Baker (Chair), Ulrike Hotopp, Frances McLeman and Sir Kenneth Parker.
Terms of reference
31 March 2023: The CMA has referred the anticipated acquisition by UnitedHealth Group Incorporated of EMIS Group Plc for an in-depth investigation.
- (31.3.23)
Phase 1
Statutory timetable
Date | Action |
---|---|
17 March 2023 | Decision announced |
20 January 2023 | Launch of merger inquiry |
20 January 2023 to 3 February 2023 | Invitation to comment |
Reference decision
31 March 2023: The CMA has referred the anticipated acquisition by UnitedHealth Group Incorporated of EMIS Group Plc for an in-depth investigation, on the basis that, on the information currently available to it, it is or may be the case that this merger has resulted or may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom.
- (17.5.23)
Reference unless undertakings accepted
17 March 2023: The CMA has decided, on the information currently available to it, that it is or may be the case that this merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom. This merger will be referred for a phase 2 investigation unless the parties offer acceptable undertakings to address these competition concerns.
- (17.5.23)
- (17.3.23)
- Press release: Healthcare deal could lead to higher costs for NHS (17.3.23)
Launch of merger inquiry
20 January 2023: The CMA announced the launch of its merger inquiry by notice to the parties.
- (20.1.23)
Invitation to comment: closed
20 January 2023: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2022 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
To assist it with this assessment, the CMA invites comments on the transaction from any interested party.
These comments should be provided by the deadline set out above.
Contact
Please send written representations about any competition or public interest issues to: